フルタミド投与患者の肝障害の予測 - 多変量解析によるリスクファクターの検討 -

Abstract

肝障害の発生率は33/123で, 64%の症例は9ヵ月以内に発症していた.独立項目のχ二乗検定によるとBMI, 肝障害の既往, GPTの高値の3項目が肝障害の発生に有意と判定された.SASによる多変量解析による検討では, 肝障害の既往とGPTの高値が肝障害を増加させ, 喫煙経験が肝障害を低下させる

The antiandrogenic drug, flutamide (Odyne), is widely used in the treatment of carcinoma of prostate. It is well known that flutamide has adverse effects of liver disorders. To ascertain the risk of liver disorders before administering this drug, past history and lifestyle preferences were resurveyed in 123 patients who had been treated with flutamide. The results obtained were assessed in relation to the occurrence of liver disorders by multivariate logistic regression analysis. The incidence of liver disorders was 26% (33/123), with 64% of the disorders occurring within 9 months. The chi-square test for dependent variables revealed that three variables, i.e., body mass index, past history of liver disorders and elevated glutamic-pyruvic transaminase levels were significantly related to the incidence of liver disorders (p > 0.05). Multivariate analysis indicated that a history of liver disorders and elevated alanine aminotransferase (ALT) levels were related to a higher incidence of liver disorders. Elevated ALT levels were associated with a higher incidence of liver disorders and smoking was related to a lower incidence of the liver disorders.